

Treat the root cause:

Chronic Inflammation





Think Outside the Eye

Treat periocular inflammation

Do your patients suffer from dry, itchy, red or burning eyes?

Periocular inflammatory conditions, such as Rosacea and eyelid telangiectasia, affect millions of Americans every year. Rosacea and Telangiectasia can have a significant impact on quality of life with visible symptoms such as redness, swelling and irritation.

When the disease manifests in the periocular region, it may lead to ocular conditions. Over 80% of Rosacea patients suffer from inflammatory ocular conditions, such as Meibomian Gland Dysfunction (MGD)¹.

Optima IPL is a drug-free, drop-free solution that combines Intense Pulsed Light (IPL) and Lumenis unique Optimal Pulse Technology (OPTTM) and is intended to treat ~20 different skin indications, including Rosacea and other skin inflammatory conditions.

"Although rosacea is predominantly a skin condition, it often leads to eyelid and ocular surface inflammation, which can then trigger Meibomian Gland Dysfunction (MGD)" ²

(Ronald N. Gaster, MD)

First-of-its-kind, drug-free, drop-free, light-based treatment

Unlike conventional treatments, Optima IPL uses advanced technology to deliver a controlled amount of intense pulsed light around the eye.


With every pulse of light, this first-of-its-kind, energy-based therapy works to control the inflammatory process and to stop the vicious cycle of inflammation - displacing the need for medications and providing long-lasting results.

Treat the root cause: chronic inflammation


Inflammatory skin diseases are characterized by the formation of vascular abnormalities, which release inflammatory agents. When occurring in proximity to the eyes, these mediators propagate via the orbital vasculature to the eyelids, often resulting in inflammation of the eyelids, which, in turn, may trigger ocular complications^{2,6,7}.

Optima IPL energy is selectively absorbed in the hemoglobin of abnormal blood vessels, and destroys them by thrombosis. A major source of inflammation threatening the eyelids is then removed.

Optima IPL alleviates abnormal blood vessels and reduces the level of pro-inflammatory mediators^{5,6} and Demodex mites⁷.



Optima IPL effectively reduces the inflammation



Less inflammatory markers in treated side, compared to untreated side³

Alleviates abnormal blood vessels and improves symptoms such as redness and itchiness



Courtesy of Rob Noecker, MD



After 4 months



After 6 months



Courtesy of Laura M. Periman, MD



After 2 IPL treatments

Lumenis, the inventor of IPL, is proud to present Optimal Pulse Technology (OPT™)

Uniquely designed for the periocular region

Safety

Homogenous pulses


- No spikes in energy
- The energy you choose is the energy you get

Efficacy


Reproducible pulses

 Consistent level of energy between pulses

Other IPL systems



Lumenis IPL with OPT™



Patented water cooled tip for the safe and comfortable treatment of the periocular region

SapphireCool™ chiller tip allows to:

- 1. Reach higher levels of energy for achieve optimal results
- 2. While keeping the treatment safe and comfortable for the patient



Modular system that includes additional skin conditions and aesthetic treatments

- Optima IPL is a modular system, allowing to extend your practice to additional ~20 different skin indications aesthetic treatments
- ExpertFilters[™] tailored to the skin type and condition for optimized results. All suitable for one handpiece



Technical Parameters of Optima IPL

System Specifications

Dimensions [without ResurFX]	44 x 51 x 47 cm (17 x 20 x 19 inches)
Dimensions [with ResurFX]	44 x 51 x 62 cm (17 X 20 X 24 inches)
Weight [without ResurFX]	40 kg / 88 lbs
Weight [with ResurFX]	55 kg / 121 lbs
Electrical requirements	100 – 240 VAC, 12A max., 50/60 Hz, single phase, dedicated line

Universal IPL

Spectrum	400-1200 nm
ExpertFilters	Acne (400 nm-600 nm & 800 nm-1200 nm); 515 nm; Vascular (530 nm-650 nm & 900 nm-1200 nm); 560 nm; 590 nm; 615 nm; 640 nm; 695 nm; 755 nm
Lightguides	15 x 35 mm; 8 x 15 mm, 6 mm Ø
Fluence	Up to 35 J/cm² for rectangular lightguides; Up to 56 J/cm² for the round lightguide
Pulse Duration	4-20 ms
Pulse Delay	5-150 ms
Pulse Characteristic	Multiple Sequential Pulsing
Repetition Rate	Up to 1 Hz
Cooling	Continuous contact cooling

Risks and warning (non-inclusive list):

Lumenis energy based treatments are not suitable for everyone and, like every treatment, can carry some risks. Treatment with M22 Optima IPL is contra-indicated for patients with the following conditions in the treatment area: active infections, dysplastic nevi, open lacerations, abrasions, and prolonged sun-exposure. Caution is advised for patients with photosensitivity, immune/coagulation/hormonal disorders, or a history of Herpes simplex at or near the treatment area. Side effects include (but are not limited to) discomfort, excessive edema/erythema, bruising, burns, scarring, and changes in pigmentation. Please refer to the operator manual for a complete list of intended uses, contraindications and risks.

1. Viso et al. (2014) Eur Ophthalmol Rev 8(1):13-6; 2. Gaster (2016), insert to Cataract & Refractive Surgery Today 2; 3. Liu et al. (2017) Am J Ophthalmol 183:81-90.; 4. Yin et al. (2018) Curr Eye Res 43(3):308-13; 5. Prieto et al. (2002) Lasers Surg Med 30(2):82-5; 6. Kassir et al. (2011) J Cosmet Laser Ther 13(5):216-22; 7. Papageorgiou et al. (2008) Br J Dermatol 159(3):628-32

Lumenis Ltd.

Yokneam Industrial Park

Hakidma Street 6, P.O.B. # 240

Yokneam 2069204, ISRAEL

Tel +972 4 959 9000

Lumenis (Germany) GmbH Heinrich-Hertz-Str 3 D-63303 Dreieich-Dreieichenhain GERMANY Tel +49 (0) 6103 8335 0 **AMERICAS**

San Jose, CA, USA Tel +1 408 764 3000 +1 877 586 3647 Fax +1 408 764 3999 JAPAN

Tokyo, Japan Tel +81 3 4431 8300 Fax +81 3 4431 8301 ASIA / PACIFIC

Beijing, China Tel +86 10 5737 6677 Gurgaon, India Tel +91 124 422 07 95 Kowloon, Hong Kong Tel +852 217 428 00

Fax +852 272 251 51

Risk GROUP 3

EMEA

EMEA Dreieich Dreieichenhain, Germany Tel +49 6103 8335 0 Fax +49 6103 8335 300 Roma (RM), Italy Tel +39 06 90 75 230 Fax +39 06 90 75 269 Hertfordshire, UK Tel +44 20 8736 4110

Fax +44 20 8736 4119





www.lumenis.com/Ophthalmology

The indications are only relevant where they were approved by the Regulatory Authorities. The Dry eye indication has not been cleared in the United States by the FDA.